Skip to main content

Table 1 Surveillance activities in Vanuatu, 1997–2012

From: Surveillance efforts after mass drug administration to validate elimination of lymphatic filariasis as a public health problem in Vanuatu

Year

M&E activity

Detail and location by province or evaluation unit (EU)

1997–1998

Mapping survey: baseline A survey

Nationwide, 51 villages

2000

The first year of MDA

Nationwide

2002

Sentinel site B surveys

Torba, Sanma, Malampa, Penama, 2 villages each

Spot checks

1 village Malampa, 1 village Penama, 2 hospitals

2003

Spot checks

4 hospitals

Morbidity assessment

Nationwide

2004

The last year of MDA

Nationwide

Spot checks

15 villages, North Ambrym, Malampa

2005 To 2006

Stop MDA survey

C survey/TAS 1 (all ages)

Nationwide in 30 villages per EU

EU1 (Torba, Sanma, Malampa);

EU2 (Penama);

EU3 (Shefa and Tafea)

Sentinel sites

Torba, Sanma, Penama (2 villages each).

Spot checks

6 villages of Penama (EU2)

2007

Transmission assessment survey

D survey/CTS/TAS 2

Community TAS 2 in 6–7 year olds

EU1 (Torba, Sanma, Malampa);

EU2 (Penama);

EU3 (Shefa and Tafea)

Morbidity assessment

Malampa and parts of Penama, Sanma, Shefa, Tafea

2008

Spot checks

5 villages of South Pentecost and West Ambae (Penama, EU2)

Targeted MDAa and spot checks

Targeted follow-up MDA round 1: 13 villages of North Ambrym, Malampa province (in EU1)

Spot checks followed MDA

2009

Targeted MDA

Targeted follow-up MDA round 2: North Ambrym, Malampa province (in EU1)

2010

Targeted MDA

Targeted follow-up MDA round 3: North Ambrym, Malampa province (in EU1)

Transmission assessment survey TAS 3

Community TAS 3 in EU1 and 2;

Children tested in 2 spot-check villages in EU3

2011

Spot checks and sentinel sites

Vila and Santo Hospitals

USP students

Sentinel sites EU1, EU2, EU3 (2 villages each—test and treat of former positives only)

2012

Transmission assessment survey

TAS 3 continued

Community TAS 3 in EU3

TAS 4

Community TAS 4 in EU2

Dossier preparation

Preparation of elimination dossier started

  1. aIn targeted MDA, treatment without prior testing is offered to all inhabitants >2 yrs of age in selected villages thought to have persistent high prevalence, such as villages of North Ambrym identified in 2004. See [4] for details